European Medicines Agency withdrawal for sibutramine

Archives of Disease in Childhood

Volumn 95, Issue 10, 2010, Pages 856-

  Galhardo, J ^a   Davis, N ^a   Matthai, S ^b   Shield, Julian P ^a  

^a BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^b Department of Paediatrics   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MELANOCORTIN 4 RECEPTOR; SIBUTRAMINE;

ADOLESCENT; BARDET BIEDL SYNDROME; BEHAVIOR CHANGE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE REPORT; CHROMOSOME 22Q; CHROMOSOME DUPLICATION; COHORT ANALYSIS; DRUG MARKETING; EUROPE; FEMALE; GENE MUTATION; HUMAN; LETTER; LIFESTYLE MODIFICATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL;

ADOLESCENT; APPETITE DEPRESSANTS; CYCLOBUTANES; EUROPE; FEMALE; HUMANS; LICENSURE; MALE; OBESITY; SAFETY-BASED DRUG WITHDRAWALS;

EID: 77957325994     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2010.190959     Document Type: Letter

References (4)

1. European Medicines Agency. Press release 21 January 2010. http://www.ema.europa.eu/pdfs/human/referral/sibutramine/3940810en.pdf.
2. US Food and Drug Administration. Press release 21 January 2010. Meridia (sibutramine hydrochloride): follow-up to an early communication about an ongoing safety review. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm198221.htm.
3. Van Gaal LF, Caterson ID, Coutinho W, et al.; SCOUT Investigators. Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial. Diabetes Obes Metab 2010;12:26-34.
4. Viner RM, Hsia Y, Neubert A, et al. Rise in antiobesity drug prescribing for children and adolescents in the UK: a population-based study. Br J Clin Pharmacol 2009;68:844-51.